Abstract | BACKGROUND: METHODS: RESULTS: Ki67 was found to be an independent predictor of pCR in multivariate analysis (odds ratio [OR], 3.62; 95% CI, 1.21-10.8). When stratified by ER, the above significance was exclusive to ER-positive tumors (OR, 6.24; 95% CI, 1.40-27.7). Using an receiver-operating characteristic curve, we obtained moderate discriminative accuracy with an area under the curve of 0.7752 for Ki67 prediction of pCR in ER-positive tumors. In subgroup analysis, patients with high Ki67 showed significantly improved pCR rate in luminal-type disease, with a median Ki67 value of 43% in the patients who achieved pCR, versus 29% for those without pCR (P = .018), whereas no associations were observed in other subtypes. CONCLUSION: Our results suggest that stratification according to Ki67 levels might improve predictive significance of the response in hormone-responsive breast cancer. Even in these subtypes assumed to be less chemosensitive, some patients with highly proliferative tumors derive a significant benefit from chemotherapy, and consequently it is important to identify them.
|
Authors | Aiko Sueta, Yutaka Yamamoto, Mitsuhiro Hayashi, Satoko Yamamoto, Toko Inao, Mutsuko Ibusuki, Keiichi Murakami, Hirotaka Iwase |
Journal | Surgery
(Surgery)
Vol. 155
Issue 5
Pg. 927-35
(May 2014)
ISSN: 1532-7361 [Electronic] United States |
PMID | 24582496
(Publication Type: Evaluation Study, Journal Article)
|
Copyright | Copyright © 2014 Mosby, Inc. All rights reserved. |
Chemical References |
- Biomarkers, Tumor
- Ki-67 Antigen
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
(metabolism)
- Biopsy
- Breast
(metabolism, pathology)
- Breast Neoplasms
(classification, drug therapy, metabolism)
- Drug Therapy
- Female
- Follow-Up Studies
- Humans
- Ki-67 Antigen
(metabolism)
- Middle Aged
- Multivariate Analysis
- Neoadjuvant Therapy
- Predictive Value of Tests
- Prognosis
- Retrospective Studies
- Treatment Outcome
|